Deutsche medizinische Wochenschrift (1946)

Treatment recommendations for type 2 diabetes from the European diabetes association

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

New clinical recommendations emphasize cardiovascular risk over HbA1c levels in treating type 2 diabetes patients.

  • Individual patient profiles and cardiovascular risk are prioritized in treatment strategies.
  • For patients at high or very high cardiovascular risk, GLP-1 receptor agonists or SGLT-2 inhibitors are recommended.
  • SGLT-2 inhibitors are specifically highlighted for patients with chronic heart failure or those at increased cardiovascular risk.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

D. Müller-Wieland hat in den letzten drei Jahren Honorare für Beratung und Vorträge der folgenden Firmen erhalten: Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk und Sanofi.N. Marx hat in den letzten drei Jahren Vorträge gehalten für Boehringer Ingelheim, Sanofi-Aventis, MSD, AstraZeneca, Lilly, NovoNordisk; N. Marx hat Forschungsprojekte durchgeführt, die von Boehringer Ingelheim unterstützt wurden, und als Berater für Amgen, Boehringer Ingelheim, Sanofi­Aventis, MSD, BMS, AstraZeneca, NovoNordisk fungiert. Sämtliche Honorare sind an die Uniklinik Aachen gegangen, und N. Marx hat für seine Tätigkeit keine persönlichen Honorare erhalten. Darüber hinaus hat die Uniklinik Aachen Honorare für die Leitung klinischer Studien von Boehringer Ingelheim und Novo Nordisk erhalten.
PubMed

Related papers

Dec '22
Use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes patients based on 2019 European and American treatment guidelines
top 5% journal
cited by 32 papers
research support, non-u.s. gov't
Jun '20
Using 2019 European guidelines to identify who with type 2 diabetes in Scotland should start or add newer diabetes drugs
cited by 17 papers
historical article
Jan '21
Comparing SGLT-2 inhibitors and GLP-1 receptor agonists for type 2 diabetes: review and analysis of clinical trials
top 5% journal
cited by 520 papers
systematic review
Oct '19
Using SGLT-2 inhibitors and GLP-1 receptor agonists together to target multiple organ problems in type 2 diabetes
cited by 18 papers
journal article
Mar '21
Heart, kidney, and other diabetes outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in type 2 diabetes: a nationwide study
top 2% journal
cited by 50 papers
observational study
May '21
Current National Patterns of Who Qualifies for and Uses New Heart-Protecting Diabetes Drugs in Type 2 Diabetes
top 5% journal
cited by 56 papers
research support, n.i.h., extramural

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief